Cargando…
Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial
Body composition parameters have been reported to be prognostic factors in patients with oncologic diseases. However, the available data on patients with HCC are conflicting. The aim of this study was to assess the impact of body composition on survival in patients with HCC treated with sorafenib or...
Autores principales: | Surov, Alexey, Thormann, Maximilian, Hinnerichs, Mattes, Seidensticker, Max, Seidensticker, Ricarda, Öcal, Osman, Schütte, Kerstin, Zech, Christoph J., Loewe, Christian, van Delden, Otto, Vandecaveye, Vincent, Verslype, Chris, Gebauer, Bernhard, Sengel, Christian, Bargellini, Irene, Iezzi, Roberto, Berg, Thomas, Klümpen, Heinz J., Benckert, Julia, Gasbarrini, Antonio, Amthauer, Holger, Sangro, Bruno, Malfertheiner, Peter, Omari, Jazan, Wienke, Andreas, Ricke, Jens, Pech, Maciej |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208699/ https://www.ncbi.nlm.nih.gov/pubmed/37219875 http://dx.doi.org/10.1097/HC9.0000000000000165 |
Ejemplares similares
-
Extrahepatic Disease in Hepatocellular Carcinoma: Do We Always Need Whole-Body CT or Is Liver MRI Sufficient? A Subanalysis of the SORAMIC Trial
por: Geyer, Thomas, et al.
Publicado: (2022) -
Prognostic role of radiomics‐based body composition analysis for the 1‐year survival for hepatocellular carcinoma patients
por: Saalfeld, Sylvia, et al.
Publicado: (2023) -
Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial
por: Öcal, Osman, et al.
Publicado: (2021) -
Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression
por: Öcal, Osman, et al.
Publicado: (2022) -
Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib
por: Öcal, Osman, et al.
Publicado: (2022)